EditorialKommentar
Outcomes that need to be assessed in clinical trials for cutaneous neurofibromas in people with neurofibromatosis type 1
British Journal of Dermatology · 2024
DOI: 10.1093/bjd/ljad515 ↗Kurz gefasst
Editorial in der Zeitschrift British Journal of Dermatology, 2024. Hauptthemen laut MEDLINE: Neurofibromatosis 1, Neurofibroma, Connective Tissue Diseases, Skin Neoplasms.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Neurofibromatosis 1NeurofibromaConnective Tissue DiseasesSkin NeoplasmsHumansOutcome Assessment, Health Care
Zitieren
APA
(2024). Outcomes that need to be assessed in clinical trials for cutaneous neurofibromas in people with neurofibromatosis type 1. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljad515
Vancouver
Outcomes that need to be assessed in clinical trials for cutaneous neurofibromas in people with neurofibromatosis type 1. British Journal of Dermatology. 2024. doi:10.1093/bjd/ljad515
BibTeX
@article{euvimed2024,
title = {Outcomes that need to be assessed in clinical trials for cutaneous neurofibromas in people with neurofibromatosis type 1},
journal = {British Journal of Dermatology},
year = {2024},
doi = {10.1093/bjd/ljad515}
}
EUVIMED